Experimental Arm:Almonertinib 110mg PO once daily

3 trials

Sponsors

Cancer Hospital Chinese Academy of Medical Sciences, The First Affiliated Hospital of Guangzhou Medical University, Cancer Hospital Chinese Acadmey of Medical Sciences, Shenzhen Center

Conditions

NSCLC

Phase 2

Almonertinib vs. Erlotinib / Chemotherapy for Neo-Adjuvant Treatment of Stage IIIA-N2 EGFR-Mutated NSCLC: a Multicenter, Open-Label, Phase II Randomized Controlled Trial

Active, not recruitingChiCTR2000033677

The First Affiliated Hospital of Guangzhou Medical UniversityNSCLC

Start: 2020-09-01Updated: 2021-05-17

Phase 3

Almonertinib Versus Almonertinib Plus Chemotherapy as First-Line Treatment in Patients With EGFR Mutation Positive With Concomitant Non-EGFR Driver Gene Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer: a Multicenter, Open-Label, Randomized, Control Phase III Study (ACROSS 1)

RecruitingChiCTR2000032354

Cancer Hospital Chinese Academy of Medical SciencesNSCLC

Start: 2020-08-01Updated: 2021-12-13

Almonertinib Plus Radiotherapy compared with Concurrent RadioChemotherapy in the treatment of unresectable EGFR-mutated stage III Non-Small Cell Lung Cancer: a Multicenter, Open-Label, Randomized, Control Phase III Study

Active, not recruitingChiCTR2000040590

Cancer Hospital Chinese Acadmey of Medical Sciences, Shenzhen CenterNSCLC

Start: 2020-12-01Updated: 2021-03-15

Related Papers

Survival of induction aumolertinib followed by aumolertinib and concurrent radiotherapy (RT) in unresectable <i>EGFR</i> -mutated stage III NSCLC: Final analysis of the phase III ADVANCE trial and real-world data.

Journal of Clinical Oncology2025-05-281 citations